Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.

Current opinion in hematology - 1 Mar 2015

Santini Valeria

Abstract excerpt

PURPOSE OF REVIEW: Hypomethylating agents, azacitidine and decitabine, are successfully used for the treatment of myelodysplastic syndromes (MDS). In spite of improvement in survival, MDS is still incurable without hematopoietic stem cell transplant, and in case of absence/loss of response to hypomethylating agents, outcome is poor. The purpose of this article is to provide an overview of the new approach to MDS,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to DNA Methylation
Share to DNA Modification Methylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematopoietic Stem Cell Transplantation

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Prognosis

Share to Treatment Outcome

Source

Identifiers

PMID: 25603477
DOI: 10.1097/MOH.0000000000000117

Genes

ASXL1
IDH2
TET2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.PMID 25603477Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic SyndromeSemantic proximity Read ↗

Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?Semantic proximity Read ↗

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?Semantic proximity Read ↗

Optimizing hypomethylating agents in myelodysplastic syndromesSemantic proximity Read ↗

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Established and emerging targeted therapies in the myelodysplastic syndromes.Semantic proximity Read ↗

[Hypomethylating agents for the treatment of myelodysplastic syndromes].Semantic proximity Read ↗

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.Semantic proximity Read ↗

Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes.Semantic proximity Read ↗

Myelodysplastic Syndromes: A New Decade.Semantic proximity Read ↗

Current and emerging strategies for management of myelodysplastic syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.